The Second WHO integrated meeting on development and clinical trials of Influenza vaccines that induce broadly protective and long-lasting immune responses
5-7 May 2014, Hotel Intercontinental, Geneva, Switzerland
Background, meeting objectives and expected outcomes
One of the objectives of the IVB department is to promote the development of influenza vaccines that induce broadly protective and long lasting immune responses. These novel vaccines would overcome problems with the current vaccination strategy and likely be more acceptable in developing countries.
Such vaccines would also contribute to the control of epidemics and potential pandemics. During 2004-2011, IVR convened eleven meetings on the development and evaluation of novel influenza vaccines. The technical reports of each of these conferences were published in leading journals.
In 2012, IVR decided to combine its annual meeting on clinical trials evaluating pandemic influenza vaccines with its biennial meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses. The first integrated meeting was held in January 2013 at the Hong Kong Baptist University.
The current meeting was held in Geneva and was fully funded by the CDC-WHO Collaborative Agreement.
- review the current status of research in the area of new influenza vaccines, focusing on strategies to induce broadly protective and long-lasting immune responses;
- discuss recent data from clinical trials of pandemic and seasonal influenza vaccines; and
- define a research agenda for the accelerated development of novel influenza vaccines.
- research agenda for the accelerated development of cross protective influenza vaccines; and
- publication of a technical report in the peer-reviewed literature.